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Mutations in exon 20 of the human epidermal growth fac-tor receptor 2 (HER2) gene are proliferative drivers in 
lung cancer, and inducible expression of the in-frame inser-
tion/duplication A775_G776insYVMA (HER2(YVMA)) 
drives the development of murine adenosquamous lung 
tumors.1 Interestingly, clinical cases of lung cancer harbor-
ing HER2 mutations respond to neratinib plus temsirolimus,2 
trastuzumab,3,4 or afatinib monotherapy (a pan-epidermal 
growth factor receptor [EGFR] kinase inhibitor),4,5 although 
these benefits are not conclusive.
CASE REPORT
We present a case of a 48-year-old woman who had 
never smoked with discordant HER2 mutations in her paired 
primary lung and corresponding metastatic tumors. The pri-
mary HER2 mutant adenocarcinoma responded to afatinib, 
although the wild-type metastatic brain tumor did not. Her 
initial chest computed tomography (CT) in July 2012 revealed 
a 3.8 cm mass in the right lower lobe with mediastinal lymph-
adenopathy and pleural effusion. She was diagnosed with 
stage IV lung adenocarcinoma confirmed by tumor biopsy and 
pleural effusion cytology. The adenocarcinoma had no EGFR/
KRAS mutations or anaplastic lymphoma kinase translocation. 
We sequenced exons 18–21 of HER2 in the lung tumor and 
pleural effusion cells, and both found a rare exon 20 muta-
tion (P780_Y781insGSP; Fig. 1A). Tumor collection, the 
mutational analyses, and the patient’s clinical features were 
obtained based on protocols approved by the Institutional 
Review Board and of the patient provided written informed 
consent. The response rate or progression was measured in 
both lung and brain according to RECIST 1.1 criteria.6
From July 2012 to February 2014, the patient was sub-
sequently treated with six cycles of pemetrexed plus cisplatin 
(partial response, PR), two cycles of paclitaxel (progressive dis-
ease, PD), and eight cycles of gemcitabine plus cisplatin (first 
four cycles) (stable disease). Repeated effusion block showed 
the same HER2(P780_Y781insGSP) mutation. After disease 
progression, she received 40 mg afatinib daily for 6 weeks and 
30 mg daily thereafter. The interval from initial diagnosis of 
lung cancer to start of afatinib treatment was 20 months. Chest 
CT before/three months after afatinib treatment revealed PR 
in primary lung tumor, (Fig. 1C, E), indicating that the P780_
Y781insGSP mutation induced sensitivity to afatinib treatment. 
However, a PD was observed by brain CT (Fig. 1D, F), which 
revealed a tumor growth at the cerebellum. The brain tumor was 
excised, and pathologic examination revealed metastatic lung 
adenocarcinoma with a positive thyroid transcription factor-1 
staining and wild-type HER2 (Fig. 1B). Using next-generation 
sequencing method, we further confirmed that the HER2(P780_
Y781insGSP) mutation frequency can be detected in primary 
lung tumor (63%) and effusion block (96%) but not in brain 
tumor (0%). The results were consistent with the data obtained 
from Sanger sequencing. With the depth (greater than 30,000) 
of next-generation sequencing, we can confidently rule out the 
possibility that the false positive mutation detected in primary 
lung tumor, and the false negative mutation in brain tumor 
caused by lack of detection sensitivity.
She continued afatinib for total 4 months. However, a 
chest radiological progressive disease was observed, and she 
received two cycles of docetaxel (primary lung PD and brain 
tumor stable disease). Subsequently, she received three cycles 
of vinorelbine plus trastuzumab, which resulted in primary 
lung PR and brain PD with new brain tumors. She received 
whole brain radiation therapy and ventriculoperitoneal shunt 
creation for communicating hydrocephalus. She was under 
supportive care till February 2015.
DISCUSSION
Afatinib is an oral irreversible pan inhibitor of the 
EGFR family, including HER2.7 To determine whether cells 
harboring the HER2 mutation were able to respond to afatinib 
treatment, we analyzed transfected Ba/F3 cells. We found that 
Ba/F3 cells expressing both HER2(P780_Y781insGSP) and 
HER2(YVMA) were able to similarly enhance HER2 phos-
phorylation (Fig. 2A). Interestingly, Ba/F3 cells expressing 
P780_Y781insGSP had increased sensitivity to afatinib, with 
a lower median inhibitory concentration (0.002 μM) than 
HER2(YVMA) cells (0.015 μM; Fig. 2B), indicating that lung 
tumors harboring the HER2(P780_Y781insGSP) mutation 
should be good candidates for afatinib treatment.
The incidence of the HER2(P780_Y781insGSP) muta-
tion in lung adenocarcinoma is low. Recently, we identified 
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total 39 HER2-mutated cases among 990 lung adenocarci-
noma in our cohort study, and only four cases (10%) were 
HER2(P780_Y781insGSP; Gow, C.H. and Shih, J.Y., unpub-
lished data). In published literature, only one case has been 
reported with clinical sensitivity to afatinib monotherapy with 
rapid disappearance of all disease-related symptoms after 4 
months.5 Our case further supports the finding that afatinib 
is a potentially effective monotherapy for patients with lung 
adenocarcinoma harboring this rare mutation. Besides, a new 
clinical phase II trial (ETOP NICHE) with afatinib in lung 
cancer patients with HER2ins mutation is planned.
In conclusion, the unique HER2(P780_Y781insGSP) 
mutation conferred clinical and in vitro sensitivity to afatinib. 
However, the corresponding metastatic brain tumor had a dis-
cordant sequence and response to afatinib. Surgical treatment 
for HER2 mutation identification and symptom relief could be 
an optimal strategy in this rare case.
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FIGURE 1. A, B, Sequencing of exon 20 of HER2 reveals 
GGCTCCCCA insertion (P780_Y781insGSP; red font) in the 
primary lung tumor, although exon 20 in the metastatic brain 
tumor is wild-type. C, D, Computed tomography images 
show the patient’s lungs and brain after the failure of several 
chemotherapy agents, and before afatinib treatment. E, F, 
Computed tomography images of the patient’s lungs and 
brain show a significant response to afatinib treatment after 
3 months in the primary right lower lung tumor, and disease 
progression in the right metastatic cerebellar tumor.
FIGURE 2. A, Enhancing HER2 phosphorylation in Ba/F3 
cells expressed the HER2 mutants. Whole cell lysates from 
H1299 (expressing wild-type HER2, as a control) and Ba/
F3 cells expressing different HER2 mutants were collected 
for the detection of ErbB2, phospho-ErbB2 (p-ErbB2), 
and α-tubulin was used as loading controls. Data shown 
are representative of three independent experiments that 
yielded similar results. The p-ErbB2/ErbB2 ratio was similar 
in both HER2 mutants expressing cells, but was very low 
in wild-type HER2 expressing cells. B, Afatinib-dependent 
growth inhibition in Ba/F3 cells expressed the HER2 mutant. 
Ba/F3 cells expressing mutant P780_Y781insGSP or A775_
G776insYVMA growing in the absence of interleukin-3, 
or expressing vector in the presence of interleukin-3 (as a 
control) were incubated with the indicated concentrations 
of afatinib for 72 hours. Cell viability was measured using 
the 3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide assay. Points Average of two experiments (each 
performed in triplicate); bars standard deviation.
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